Chemoreflex testing to assess interactions between central and peripheral chemoreflexes in human hypertension.

niversity of Auckland0 个研究点目标入组 30 人开始时间: 2019年12月12日最近更新: 2022年3月28日

适应症

试验速览

暂无简介。

•Patients with essential hypertension (Stage 2, treated controlled or uncontrolled; office SBP greater than 140 mmHg or DBP greater than 90 mmHg);
•- Normotensive controls (office SBP less than 120 mmHg and DBP less than 80 mmHg);
•- BMI less than 35 kg.m2.

•Significant arrhythmias (e.g., atrial fibrillation, previous VT / significant ventricular ectopy)
•Significant valvular heart disease
•Previous coronary artery bypass surgery
•Primary angioplasty for acute ST elevation
•Myocardial infarction
•Severe left ventricular dysfunction
•Recent (< 3 months) ischemic stroke
•Current smoker
•Body mass index < 18 kg/m2.
•Current pregnancy
•Users of recreational drugs
•Abusers of alcohol
•Inability to fully or appropriately provide consent (e.g., language issue, reading capability)
•Underlying medical conditions, which in the opinion of the Investigator place the participant at unacceptably high risk for participating in the study.
•Chronic and systemic illness including:
•Severe respiratory disease (e.g., chronic obstructive pulmonary disease);
•Severe, uncontrolled type II diabetes;
•Current active treatment for cancer
•Connective tissue or inflammatory disease
•Neurological disease
•Infection or pyrexial illness
•Uncontrolled thyroid disorders
•Renal impairment (e.g., chronic kidney disease with creatinine clearance <29 ml/min)

发起方

niversity of Auckland